Streetbeat News

Analyst Ratings

NVDA

Stifel analyst Ruben Roy maintains a Hold rating on NVIDIA (NASDAQ:NVDA) and raises the price target from $300 to $370.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 12:43 pm

SPLK

BTIG analyst Gray Powell maintains a Buy rating on Splunk (NASDAQ:SPLK) and raises the price target from $121 to $128.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 12:42 pm

ADI

Truist Securities analyst William Stein maintains a Buy rating on Analog Devices (NASDAQ:ADI) but lowers the price target from $251 to $213.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 12:41 pm

NVDA

B of A Securities analyst Vivek Arya maintains a Buy rating on NVIDIA (NASDAQ:NVDA) and raises the price target from $340 to $450.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 12:41 pm

AMZN

EQT

UBER

UNH

CNBC's 'Halftime Report Final Trades' featured recommendations for UnitedHealth Group, Uber Technologies, EQT Corporation, and Amazon.com. UnitedHealth was deemed oversold, while Uber plans to launch 25,000 electric vehicles in India. EQT started a tender offer for 6.125% senior notes due 2025, and Amazon's price target was raised by Mizuho.

Portfolio Pulse from Lisa Levin

May 25, 2023 | 12:31 pm

MBLY

Wells Fargo initiated coverage on Mobileye with an Overweight rating and a $50 price target, leading to higher trading of the stock.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 12:29 pm

CASY

RBC Capital analyst Irene Nattel maintains a Sector Perform rating on Casey's General Stores (NASDAQ:CASY) and raises the price target from $273 to $280.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 12:27 pm

NTNX

RBC Capital analyst Matthew Hedberg maintains an Outperform rating on Nutanix (NASDAQ:NTNX) and raises the price target from $33 to $38.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 12:27 pm

LTRN

EF Hutton analyst Michael King assumes Lantern Pharma (NASDAQ:LTRN) with a Buy rating and maintains a price target of $11.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 12:26 pm

HOWL

EF Hutton analyst Michael King assumes Werewolf Therapeutics (NASDAQ:HOWL) with a Buy rating and maintains a price target of $8.3.

Portfolio Pulse from Benzinga Newsdesk

May 25, 2023 | 12:25 pm